Clinical Scorecard: Evaluating Photon-Counting Computed Tomography in Esophageal Cancer: Relationship Between Iodine Levels, Histopathological Findings, and Neoadjuvant Radiochemotherapy Response

At a Glance

Key Highlights

• Photon-counting CT (PCCT) enables quantitative iodine concentration (IC) measurement to improve tumor characterization and staging in esophageal cancer.
• Normalized iodine concentration (NIC) correlates with histopathological tumor features and can predict response to neoadjuvant radiochemotherapy (NARC).
• NIC measurement shows good interobserver reliability and may serve as a non-invasive biomarker for treatment planning and monitoring.

Guideline-Based Recommendations

Diagnosis

• Use PCCT with iodine mapping in the portal venous phase for initial staging of locally advanced esophageal cancer.
• Perform histopathological confirmation including tumor type, grade, lymphovascular invasion, and proliferation index (Ki-67).

Management

• Apply neoadjuvant radiochemotherapy as standard treatment for resectable locally advanced esophageal adenocarcinoma and concurrent chemoradiotherapy followed by surgery for squamous cell carcinoma.
• Consider NIC values from PCCT as adjunctive information to predict tumor response to neoadjuvant therapy.

Monitoring & Follow-up

• Repeat PCCT imaging post-neoadjuvant therapy to assess changes in iodine concentration and correlate with histopathological tumor regression grading.
• Use NIC and Becker classification to evaluate treatment efficacy and guide further management.

Risks

• Exclude patients with small tumors (<5 mm), non-contrast-enhanced scans, or significant imaging artifacts that impair interpretation.
• Ensure accurate ROI placement to avoid partial volume effects in iodine quantification.

Patient & Prescribing Data

105 patients with histologically confirmed locally advanced esophageal adenocarcinoma or squamous cell carcinoma undergoing PCCT and neoadjuvant radiochemotherapy

NIC derived from PCCT correlates with tumor histopathology and can predict response to neoadjuvant radiochemotherapy, potentially guiding personalized treatment strategies.

Clinical Best Practices

• Perform PCCT imaging in the portal venous phase with weight-adjusted contrast injection and standardized acquisition parameters.
• Use dual independent radiologist readings blinded to histopathology to ensure reliable NIC measurement.
• Calculate normalized iodine concentration (NIC) by ratio of tumor IC to aortic IC to account for physiological variability.
• Integrate NIC assessment with histopathological evaluation including Ki-67 proliferation index and Becker regression grading for comprehensive tumor response assessment.

References

• Esophageal cancer epidemiology and standard imaging
• Neoadjuvant radiochemotherapy guidelines for esophageal cancer
• Photon-counting CT technology and advantages
• Iodine quantification in tumor characterization
• Iodine concentration predicting treatment response in rectal cancer
• Becker classification for tumor regression grading